RAPP

Rapport Therapeutics, Inc. RAPP

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$0

Quarter to Jun 30

Net income

$-56.62M

Quarter to Jun 30

Free cash flow

$-41.53M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.13B total
FMR LLC
$298.89M+0.1%
TRV GP V, LLC
$261.71M-12.0%
ARCH Venture Management, LLC
$155.38M0.0%
Capital International Investors
$121.76M-5.7%
GOLDMAN SACHS GROUP INC
$121.28M-1.1%
BlackRock, Inc.
$112.50M+7.7%
Cormorant Asset Management, LP
$110.74M-10.1%
Sofinnova Ventures Inc
$79.36M0.0%
JOHNSON & JOHNSON
$74.36M0.0%
Polar Capital Holdings Plc
$67.03M-2.1%
BAKER BROS. ADVISORS LP
$64.47M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$56.11M+1.6%
TRV GP VI, LLC
$40.39M0.0%
STATE STREET CORP
$34.12M+7.8%
GEODE CAPITAL MANAGEMENT, LLC
$33.07M+10.0%
PRICE T ROWE ASSOCIATES INC /MD/
$32.81M-9.1%
PERCEPTIVE ADVISORS LLC
$32.23M+14.8%
Vestal Point Capital, LP
$30.42M-49.2%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$26.84M-29.9%
Siren, L.L.C.
$26.73M0.0%
Capital World Investors
$22.99M+2.8%
ALLIANCEBERNSTEIN L.P.
$21.70M-4.7%
T. Rowe Price Investment Management, Inc.
$16.39M-36.6%
DIMENSIONAL FUND ADVISORS LP
$15.09M+61.3%
VANGUARD PORTFOLIO MANAGEMENT LLC
$15.00M+12.2%
See all 161 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/RAPP

Earnings Per Share

13fpro.ai/company/RAPP

Loading ratio trend…

RAPP insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Rapport Therapeutics, Inc. (RAPP): stock profile, AI score and financials

Rapport Therapeutics, Inc. (RAPP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RAPP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Rapport Therapeutics, Inc. reports net income of $-56.6M, free cash flow of $-41.5M. Top institutional holders of RAPP by reported 13-F value include FMR, TRV GP V, ARCH Venture Management, based on the most recent SEC filings. RAPP trades on the Nasdaq exchange and files with the SEC under CIK 2012593. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RAPP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rapport Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 2012593 →